LINCOMYN 110MGG SOLUBLE POWDER

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

Lincomycin Hydrochloride (monohydrate)

Boleh didapati daripada:

Life Biopharma Sdn. Bhd.

INN (Nama Antarabangsa):

Lincomycin Hydrochloride (monohydrate)

Unit dalam pakej:

100 gm; 200 gm; 500 gm; 1 kg

Dikeluarkan oleh:

Life Biopharma Sdn. Bhd.

Risalah maklumat

1
FOR ANIMAL USE ONLY
BRAND OR PRODUCT NAME :
LINCOMYN 110MG/G SOLUBLE POWDER
NAME AND STRENGTH OF ACTIVE SUBSTANCE(S)
Each gram of LINCOMYN 110MG/G SOLUBLE POWDER contains Lincomycin 110
mg which is equivalent to Lincomycin Hydrochloride 124.74 mg.
PRODUCT DESCRIPTION
A white or almost white powder.
TARGET SPECIES
Swine and chicken (broiler).
PHARMACODYNAMICS
Lincomycin is a lincosamide antibiotic produced by _Streptomyces
lincolensis_. Lincomycin is bacteriostatic in action inhibiting the
protein synthesis predominantly by binding to the
50S ribosomal subunits of bacteria. Depending on the sensitivity of
micro-organisms, and on the concentration of the active substance the
protein synthesis inhibition antibacterial
action can either be bacteriostatic or bactericide. Lincomycin is
active against a wide range of Gram-positive micro-organisms,
including also anaerobic bacteria such as _clostridia_
and _Brachyspira spp._, as well as _Mycoplasma spp._ Lincomycin has no
activity against Gram-negative bacteria, such as _Klebsiella spp._,
_Pasteurella spp._ and _Salmonella spp._ The
resistance rate against lincomycin is slow, multiple-step type.
Plasmid mediated infectious resistance is also described. No
cross-resistance has been described with penicillin,
ampicillin, cephalosporins, tetracyclines, or novobiocin.
PHARMACOKINETICS
Lincomycin is rapidly absorbed orally. After oral administration, the
absorbed lincomycin is eliminated through the bile and faeces in
active form or as metabolites. _Lincomycin_ is also
_excreted_ in the milk. Lincomycin reaches inflammation site by
polymorf neutrophil granulocytes which explains its fast absorption
and distribution, efficient penetration and targeted
activity in difficult to reach tissues.
INDICATIONS
Treatment of infection caused by mycoplasma and bacteria_ _susceptible
to lincomycin for example:
Pigs: swine dysentery caused by _Brachyspira hyodysenteriae_,
mycoplasma pneumonia associated with _Mycoplasma hyopneumoniae _.
Chicken: necrotic enteritis caused by _Clostridium

Ciri produk

1
FOR ANIMAL USE ONLY
BRAND OR PRODUCT NAME :
LINCOMYN 110MG/G SOLUBLE POWDER
NAME AND STRENGTH OF ACTIVE SUBSTANCE(S)
Each gram of LINCOMYN 110MG/G SOLUBLE POWDER contains Lincomycin 110
mg which is equivalent to Lincomycin Hydrochloride 124.74 mg.
PRODUCT DESCRIPTION
A white or almost white powder.
TARGET SPECIES
Swine and chicken (broiler).
PHARMACODYNAMICS
Lincomycin is a lincosamide antibiotic produced by _Streptomyces
lincolensis_. Lincomycin is bacteriostatic in action inhibiting the
protein synthesis predominantly by binding to the
50S ribosomal subunits of bacteria. Depending on the sensitivity of
micro-organisms, and on the concentration of the active substance the
protein synthesis inhibition antibacterial
action can either be bacteriostatic or bactericide. Lincomycin is
active against a wide range of Gram-positive micro-organisms,
including also anaerobic bacteria such as _clostridia_
and _Brachyspira spp._, as well as _Mycoplasma spp._ Lincomycin has no
activity against Gram-negative bacteria, such as _Klebsiella spp._,
_Pasteurella spp._ and _Salmonella spp._ The
resistance rate against lincomycin is slow, multiple-step type.
Plasmid mediated infectious resistance is also described. No
cross-resistance has been described with penicillin,
ampicillin, cephalosporins, tetracyclines, or novobiocin.
PHARMACOKINETICS
Lincomycin is rapidly absorbed orally. After oral administration, the
absorbed lincomycin is eliminated through the bile and faeces in
active form or as metabolites. _Lincomycin_ is also
_excreted_ in the milk. Lincomycin reaches inflammation site by
polymorf neutrophil granulocytes which explains its fast absorption
and distribution, efficient penetration and targeted
activity in difficult to reach tissues.
INDICATIONS
Treatment of infection caused by mycoplasma and bacteria_ _susceptible
to lincomycin for example:
Pigs: swine dysentery caused by _Brachyspira hyodysenteriae_,
mycoplasma pneumonia associated with _Mycoplasma hyopneumoniae _.
Chicken: necrotic enteritis caused by _Clostridium